



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

JUL 30 2003

Mr. Richard Lenart
Quality Control & Assurance Manager
Scantibodies Laboratory, Inc.
9336 Abraham Way
Santee, CA 92071

Re: k031534
Trade/Device Name: Parathyroid Hormone (PTH) Immunoradiometric IRMA Assay
Regulation Number: 21 CFR 862.1545
Regulation Name: Parathyroid hormone test system
Regulatory Class: Class II
Product Code: CEW
Dated: May 09, 2003
Received: May 16, 2003

Dear Mr. Lenart:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure



SCANTIBODIES Laboratory, Inc.

The Power of Antibodies to Select and Detect



ISO 9001 QUALITY SYSTEM ✓

9336 Abraham Way • Santee, CA 92071-2862 USA • Phone (619) 258-9300 • Fax (619) 258-9366

Statement of Indications for Use

510(k) Number (if known): K031534

Device Name: Parathyroid Hormone (PTH) Immunoradiometric IRMA Assay

Indications For Use:

A parathyroid hormone test system is a device intended to measure the levels of parathyroid hormone in serum and plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia (abnormally high levels of calcium in the blood) and hypocalcemia (abnormally low levels of calcium in the blood) resulting from disorders of calcium metabolism.

(Please do not write below this line – continue another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X

Jean Cooper
Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K031534